GMED vs MDLN
Globus Medical vs Medline Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
MDLN
Medline Inc.
51
Watch
| Metric | GMED | MDLN |
|---|
| AI Score |
71
|
51
|
| Price |
$85.12
|
$35.02
|
| P/E Ratio |
21.45×
|
40.74×
|
| ROE |
11.8%
|
10.8%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
25.0%
|
| Debt / Equity |
0.02×
|
1.09×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
37.7
|
| Beta |
0.954
|
-0.4106
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus MDLN.
GMED leads by 20 points.
GMED scores 71/100 (Buy) versus MDLN at 51/100 (Watch).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
MDLN Committee View
40% agreement
5 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 64.1 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Weekly trend (downtrend) confirms the daily trend -- multi-timeframe agreement — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- P/E of 64.1 is expensive by classic value standards — Value
- Price-to-book of 5.0x prices in significant intangible value — Value
- Price structure making lower highs and lower lows — Technical